Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>The COVID-19 pandemic exposed profound fissures in the global health architecture, particularly regarding the distribution of life-saving immunizations. While high-income nations leveraged advanced purchase agreements and robust market incentives to secure rapid access, low-income countries (LICs) were often relegated to the end of the procurement queue. This disparity highlights critical ethical tradeoffs in vaccine development, where the necessity of assuring fair availability for LICs often conflicts with the commercial priorities of private developers [1]. Achieving global health security requires a paradigm shift that recognizes equitable distribution not merely as a moral imperative, but as a technical necessity for pandemic containment [6].</p><p>Current economic frameworks for vaccine access in LICs are largely defined by a reliance on donor-driven mechanisms and temporary relief aid [15]. These models, while essential for immediate crisis response, often fail to address the underlying structural barriers to health. Research indicates a significant correlation between health expenditure and long-term economic development [8]; however, without sustainable market-shaping interventions, LICs remain trapped in cycles of dependency. The aspiration for a "world converging within a generation" by 2035 necessitates a move away from reactive aid toward proactive investment in regional health systems [25].</p><h3>Market-Based Incentives vs. Structural Barriers</h3><p>The failure of existing market-based incentives to serve LICs is rooted in both supply-side and demand-side challenges. On the supply side, the high cost of R&D and the perceived low return on investment for diseases prevalent in LICs deter private innovation. On the demand side, even when vaccines are available, structural barriers such as weak health infrastructure and prohibitive out-of-pocket costs impede effective uptake [30]. To address these gaps, recent frameworks have proposed a shift toward sustainable regional manufacturing [14].</p><h4>Key Challenges to Equity:</h4><ul><li><strong>Market Prioritization:</strong> Dominance of markets with high purchasing power over public health needs.</li><li><strong>Dependency on Aid:</strong> Vulnerability of LICs to the volatility of international assistance [15, 19].</li><li><strong>Absorptive Capacity:</strong> Limitations in national systems to integrate and distribute new medical technologies [21].</li></ul><p>This article provides a comparative analysis of these development and access frameworks. By evaluating the efficacy of conditional economic incentives [2] and the potential of localized manufacturing [14], we aim to identify strategies that move beyond market-fixing to create resilient, equitable vaccine ecosystems for the world's most vulnerable populations.</p>
<h2>Literature Review</h2>
<h3>Historical Context: Health Expenditure and Economic Development</h3><p>The relationship between health investment and macroeconomic stability has been a subject of scholarly inquiry for decades. Early empirical studies, such as those by Krishnamurty [20], established that population health dynamics are inextricably linked to economic growth in developing nations like India. Subsequent research has reinforced that health expenditure is not merely a cost but a foundational requirement for sustainable development in low- and middle-income countries (LMICs) [8]. However, the distribution of these expenditures often fails to address the specific needs of the most vulnerable populations, leading to persistent disparities in health outcomes.</p><h3>The Economic Burden of Infectious Diseases</h3><p>Infectious diseases impose a disproportionate economic burden on LMICs, affecting both household productivity and national GDP. A systematic review of influenza in these regions indicates that the social and economic costs are substantial, often exacerbated by the lack of robust surveillance and vaccination programs [11]. This burden is further complicated by the fact that many low-income countries rely on temporary relief aid rather than long-term development assistance, which can lead to volatile consumption behavior and unstable health financing [15].</p><h3>Supply-Side Mechanisms and Vaccine Development</h3><p>Addressing vaccine inequity requires a multifaceted approach to supply-side incentives. Sustainable vaccine manufacturing in LMICs is critical to reducing dependency on high-income nations, yet it faces significant hurdles related to infrastructure and regulatory alignment [14]. Furthermore, the success of vaccine development in these regions depends on optimized clinical trial frameworks. Msusa et al. [10] identify critical success factors for conducting human challenge trials in resource-limited settings, emphasizing the need for local capacity building and ethical rigor to ensure that development processes are both efficient and equitable [1].</p><h3>Demand-Side Barriers and Socio-Economic Determinants</h3><p>Even when vaccines are available, structural and demand-side barriers often impede uptake. Research into health access determinants in low-income countries reveals that socio-economic status, education, and geographic location are primary drivers of health service utilization [12]. O’Donnell [30] argues that breaking down these barriers requires moving beyond simple supply increases to address out-of-pocket costs and weak health infrastructure. The following table summarizes the primary economic and structural barriers identified in current literature:</p><table><thead><tr><th>Barrier Category</th><th>Primary Determinants</th><th>Key Reference</th></tr></thead><tbody><tr><td>Economic</td><td>High out-of-pocket costs and lack of insurance</td><td>[30]</td></tr><tr><td>Structural</td><td>Weak national absorptive capacity and infrastructure</td><td>[21]</td></tr><tr><td>Policy-Driven</td><td>Reliance on temporary aid vs. sustainable investment</td><td>[15]</td></tr><tr><td>Socio-Economic</td><td>Income distribution and perceived economic status</td><td>[5, 7]</td></tr></tbody></table><h3>Frameworks for Equitable Access</h3><p>To bridge the gap between development and access, scholars have proposed various economic frameworks. Conditional economic incentives have shown promise in improving health outcomes for chronic conditions like HIV in LMICs [2], suggesting that similar mechanisms could be applied to enhance vaccine uptake. Furthermore, the concept of national absorptive capacity—the ability of a country to effectively utilize external resources and technology—is essential for the long-term success of health interventions [21]. Achieving the goals of the Global Health 2035 agenda requires a transition toward market-shaping policies that prioritize regional manufacturing and integrated health systems over fragmented, pathogen-specific responses [25].</p>
<h2>Methodology</h2>
<h3>Research Design and Theoretical Framework</h3><p>This study employs a comparative analysis methodology to evaluate the efficacy of economic incentives and structural barriers in vaccine ecosystems within Low-Income Countries (LICs). The research design is grounded in the <em>Medical Research Council (MRC) guidance for complex interventions</em> [22], which facilitates the evaluation of non-linear interactions between supply-side manufacturing subsidies and demand-side uptake barriers. We specifically integrate <strong>national absorptive capacity systems</strong> [21] with economic decision-making frameworks for vaccine introduction [4] to assess how institutional readiness influences the success of specific financial mechanisms.</p><h3>Data Selection and Comparative Parameters</h3><p>Our analysis synthesizes evidence from peer-reviewed literature and economic datasets spanning from 1966 to 2022. The selection criteria focused on studies addressing health expenditure [8], the economic burden of disease [11], and the sustainability of vaccine manufacturing in LIC contexts [14]. We categorized economic incentives into three primary domains: push incentives, pull incentives, and demand-side interventions. These were evaluated against structural constraints such as trade policy [17] and income distribution [5].</p><table><thead><tr><th>Incentive Type</th><th>Mechanism</th><th>Primary Target</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Push Incentives</td><td>R&D Subsidies / Challenge Trials</td><td>Product Development</td><td>[10, 14]</td></tr><tr><td>Pull Incentives</td><td>Advanced Market Commitments</td><td>Market Certainty</td><td>[1, 6]</td></tr><tr><td>Demand-Side</td><td>Conditional Cash Transfers</td><td>Uptake/Adherence</td><td>[2, 30]</td></tr></tbody></table><p><figure class="article-figure"><figcaption>Figure 1. Conceptual Framework of the Interplay Between Supply-Side Incentives and National Absorptive Capacity</figcaption></figure></p><h3>Analytical Approach to Absorptive Capacity</h3><p>To measure the feasibility of regional vaccine production and distribution, we utilized the dimensions of national absorptive capacity as defined by Khan (2022) [21]. This involves a comparative assessment of the institutional, technological, and economic infrastructures required to transition from temporary relief aid [15] to sustainable, locally-led ecosystems. The analysis specifically examines the impact of short-term IMF engagement [19] and historical agricultural development patterns [9] on modern health infrastructure investments.</p><table><thead><tr><th>Dimension of Capacity</th><th>Key Indicators</th><th>Economic Context</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Institutional</td><td>Regulatory Frameworks / Trade Policy</td><td>Market-Shaping Potential</td><td>[17, 21]</td></tr><tr><td>Infrastructure</td><td>Cold Chain / Manufacturing Facilities</td><td>Sustainable Production</td><td>[14, 28]</td></tr><tr><td>Socio-Economic</td><td>Income Distribution / Out-of-Pocket Costs</td><td>Equitable Access</td><td>[5, 12, 30]</td></tr></tbody></table><h3>Synthesis of Supply and Demand Factors</h3><p>The study evaluates the trade-offs between ethical imperatives for fair availability [1] and the economic realities faced by private developers. We applied a comparative risk assessment approach [24] to understand how behavioural and metabolic risks in LICs influence the perceived value of vaccine introduction [4]. Furthermore, we analyzed the role of trade policy and food price stability [5, 17] as indirect determinants of health access, recognizing that economic mobility [13] and perceived status [7] are critical drivers of vaccine demand.</p><table><thead><tr><th>Barrier Category</th><th>Structural Factor</th><th>Impact on Equity</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Economic</td><td>High Out-of-Pocket Expenditure</td><td>Reduced Uptake in LICs</td><td>[8, 30]</td></tr><tr><td>Logistical</td><td>Weak Health Infrastructure</td><td>Distribution Inequities</td><td>[6, 12]</td></tr><tr><td>Policy</td><td>Trade Restrictions / IP Barriers</td><td>Limited Regional Production</td><td>[1, 17]</td></tr></tbody></table><p><figure class="article-figure"><figcaption>Figure 2. Methodological Workflow for Evaluating Vaccine Introduction Decisions in Resource-Limited Settings</figcaption></figure></p><h4>Ethical and Economic Trade-offs</h4><p>Finally, the methodology incorporates a review of contingent valuation methods [23] and the psychological traits influencing economic behavior [29] to understand the demand-side resistance often encountered in vaccine rollouts. By bridging the gap between macro-economic policy and micro-level health access determinants [12], this analysis provides a holistic view of the requirements for achieving global health security goals by 2035 [25].</p>
<h2>Results</h2>
<h3>Economic Viability and Regional Manufacturing Sustainability</h3><p>The analysis reveals that while the technical establishment of vaccine manufacturing facilities in Low- and Middle-Income Countries (LMICs) is feasible, their long-term economic survival is currently precarious [14]. Sustainable production requires more than initial capital; it necessitates integrated trade policies and long-term purchase agreements to ensure market stability [17]. Findings suggest that supply-side incentives, such as the implementation of human challenge trials in local contexts, can accelerate development but must be balanced against ethical considerations regarding fair availability and resource allocation [1, 10].</p><h3>Structural Barriers to Equitable Distribution</h3><p>Demand-side barriers remain the primary bottleneck for vaccine equity. Even when supply is available, weak health infrastructure and high delivery costs per dose significantly impede uptake [3, 30]. Table 1 summarizes the primary economic barriers identified through the comparative analysis of HPV and general health access frameworks.</p><table><thead><tr><th>Barrier Category</th><th>Economic Impact</th><th>Example Disease</th><th>Ref</th></tr></thead><tbody><tr><td>Infrastructure</td><td>High delivery cost per dose</td><td>HPV</td><td>[3]</td></tr><tr><td>Financial</td><td>Out-of-pocket expenditure</td><td>Cancer Screening</td><td>[12]</td></tr><tr><td>Macroeconomic</td><td>IMF engagement constraints</td><td>General Health</td><td>[19]</td></tr></tbody></table><h3>Valuation of Indirect Benefits and Social Impact</h3><p>Our review of rotavirus and HPV vaccine rollouts indicates a consistent undervaluation of indirect effects in traditional economic assessments [16]. Standard cost-benefit analyses often overlook the social benefits and the impact on long-term economic mobility that arise from reduced disease burdens [13]. For instance, the social and economic burden of influenza in LMICs is frequently underestimated, leading to suboptimal investment in vaccine procurement [11].</p><figure class="article-figure"><figcaption>Figure 3. Integrated Model of Vaccine Absorptive Capacity and Economic Development</figcaption></figure><p>The data suggests that national absorptive capacity—defined by a country's ability to identify, internalize, and utilize external health technologies—is a critical predictor of both vaccine uptake and overall economic growth [21]. This capacity is often limited by existing health expenditure patterns and the economic burden of disease [8, 11].</p><h3>Comparative Framework of Economic Incentives</h3><p>A comparative analysis of supply-side and demand-side mechanisms (Table 2) demonstrates that market-fixing interventions (e.g., temporary relief aid) are less effective than market-shaping interventions that build local ecosystems [15, 25].</p><table><thead><tr><th>Incentive Type</th><th>Mechanism</th><th>Primary Outcome</th><th>Ref</th></tr></thead><tbody><tr><td>Supply-Side</td><td>Human Challenge Trials</td><td>Reduced R&D timelines</td><td>[10]</td></tr><tr><td>Supply-Side</td><td>Sustainable Manufacturing</td><td>Regional self-reliance</td><td>[14]</td></tr><tr><td>Demand-Side</td><td>Conditional Incentives</td><td>Improved HIV/Health uptake</td><td>[2]</td></tr><tr><td>Demand-Side</td><td>Absorptive Capacity Systems</td><td>Enhanced technology transfer</td><td>[21]</td></tr></tbody></table><p>Furthermore, macroeconomic constraints, such as those resulting from short-term IMF engagements, create fiscal volatility that discourages long-term health system investments [19]. Achieving the convergence goals of Global Health 2035 will require a transition from fragmented aid to structural economic incentives that prioritize regional manufacturing and integrated health systems [25].</p>
<h2>Discussion</h2>
<p>The findings of this comparative analysis suggest that the current global health architecture remains trapped in a reactive paradigm, prioritizing short-term relief aid over the structural transformations required for long-term health security. As noted by Levy [15], temporary assistance often functions as a consumption-smoothing mechanism rather than a catalyst for investment in public health infrastructure. This cycle of dependency is particularly evident in vaccine procurement, where low-income countries (LICs) remain reliant on donor-driven supply chains that fail to account for the economic burden of endemic diseases like influenza [11].</p><h3>From Relief Aid to Sustainable Manufacturing</h3><p>A critical tension exists between the immediate need for pandemic response and the objective of sustainable vaccine manufacturing in LICs [14]. While initiatives like COVAX aimed to bridge the gap, they often bypassed the development of national absorptive capacity [21], leaving health systems ill-equipped to manage the logistical complexities of distribution. The transition toward regional manufacturing hubs is not merely a technical challenge but an economic one, requiring a shift from 'market-fixing' to 'market-shaping' policies that incentivize local production and reduce out-of-pocket costs for the most vulnerable populations [30].</p><table><thead><tr><th>Mechanism</th><th>Short-term Relief Aid [15]</th><th>Sustainable Manufacturing [14]</th></tr></thead><tbody><tr><td>Primary Goal</td><td>Emergency consumption support</td><td>Long-term industrial capacity</td></tr><tr><td>Economic Impact</td><td>Temporary relief; high dependency</td><td>Structural growth; economic mobility [13]</td></tr><tr><td>Sustainability</td><td>Low; subject to donor volatility</td><td>High; integrated into regional trade [17]</td></tr></tbody></table><h3>Evaluating Global Health 2035 and Population Scenarios</h3><p>The 'Global Health 2035' framework proposes a generational convergence in health outcomes [25]. However, our analysis suggests that these goals are increasingly at odds with current population and mortality scenarios [26]. As fertility and migration patterns shift, the economic burden of disease will intensify in regions with the weakest health expenditure profiles [8]. Achieving convergence requires addressing the ethical tradeoffs inherent in vaccine development, where the drive for fair availability often conflicts with the intellectual property frameworks of high-income nations [1].</p><figure class="article-figure"><figcaption>Figure 4. Comparison of Convergence Goals (2035) vs. Projected Population Burdens (2100)</figcaption></figure><h3>Health as a Prerequisite for Economic Mobility</h3><p>The prevailing mentality of economic development [18] has historically viewed health improvements as a byproduct of rising GDP. We argue, following Rosenzweig [13] and Sachs et al. [28], that health is a fundamental prerequisite for economic mobility. Without robust health systems, LICs remain in a 'poverty trap' where disease outbreaks erode human capital and discourage investment. Conditional economic incentives [2] and improved access to screening for non-communicable diseases [12] must be integrated into a broader strategy that recognizes the psychological and personality traits [29] that influence health-seeking behavior and economic status [7].</p><table><thead><tr><th>Barriers to Equity</th><th>Supply-Side Factors</th><th>Demand-Side Factors [30]</th></tr></thead><tbody><tr><td>Economic</td><td>High R&D costs; IP restrictions</td><td>Out-of-pocket expenses; income loss</td></tr><tr><td>Structural</td><td>Weak manufacturing base [14]</td><td>Fragile health infrastructure; low absorptive capacity [21]</td></tr><tr><td>Policy</td><td>Market-based incentives</td><td>Lack of integrated health-expenditure frameworks [8]</td></tr></tbody></table><h4>Conclusion of Synthesis</h4><p>The comparative risk assessments of the last three decades [24] highlight a growing gap between the potential for medical innovation and the reality of global access. To bridge this divide, the global health community must move beyond the 'aid' mentality and embrace structural economic incentives that empower LICs to lead their own vaccine ecosystems. This involves not only financial investment but also a fundamental rethinking of the relationship between agriculture, food price policy, and health outcomes [5, 9], ensuring that vaccine equity is treated as a cornerstone of global economic stability rather than a charitable afterthought.</p>
<h2>Conclusion</h2>
<p>The persistent disparities in global vaccine access, starkly illuminated by the COVID-19 pandemic, underscore a critical failing of current market-based incentive structures to adequately serve the health interests of low-income countries (LICs). Our comparative analysis reveals that while supply-side mechanisms, such as sustainable manufacturing initiatives [14], are vital, their efficacy is often curtailed by significant demand-side barriers, including fragile health infrastructure and prohibitive out-of-pocket costs [30]. The inherent ethical tradeoffs in ensuring fair availability [1] frequently clash with the economic priorities of private developers, demonstrating that relying solely on market forces exacerbates existing inequities.</p><p>Achieving genuine global health security by 2035 [25] necessitates a fundamental paradigm shift. We must transition from reactive, temporary relief aid [15] towards proactive, structural economic incentives that foster self-reliance and resilience within LICs. This requires policy interventions that move beyond merely 'market-fixing' to actively 'market-shaping,' cultivating sustainable, locally-led vaccine ecosystems.</p><p>Key policy recommendations emerge from this analysis. First, the institutionalization of regional manufacturing hubs is paramount, ensuring sustainable vaccine production and supply closer to the point of need [14]. Second, robust monitoring of national absorptive capacity, leveraging panel data, is crucial for understanding and enhancing countries' abilities to effectively procure, distribute, and administer vaccines [21, 13]. This approach recognizes that effective vaccine uptake is not solely a matter of supply but also of a nation's capacity to integrate health interventions.</p><p>Furthermore, future policy must adopt a holistic view of public health, integrating sexual and reproductive health rights into broader vaccine frameworks [27]. Such an approach acknowledges the interconnectedness of health determinants and strengthens overall health systems. Ultimately, mitigating the risks of future pandemics requires aligning a country's economic status with life satisfaction [7] and investing in robust public health infrastructure. This comprehensive strategy will ensure that the economic burden of influenza [11] and other pathogens is addressed through equitable, sustainable, and locally empowered vaccine access, rather than through fragmented and insufficient market-driven solutions.</p>
<h2>References</h2>
<ol class="references">
<li>Gurwitz, D.. Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries. Vaccine. 2021;39(7), 1027. https://doi.org/10.1016/j.vaccine.2021.01.015</li>
<li>Galárraga, O., Sosa-Rubí, S. G.. Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countries. The Lancet HIV. 2019;6(10), e705-e714. https://doi.org/10.1016/s2352-3018(19)30233-4</li>
<li>Denny, L.. HPV vaccine introduction and implementation in Low- and Middle-Income Countries. Vaccine. 2022;40, A1. https://doi.org/10.1016/j.vaccine.2022.02.074</li>
<li>Hutubessy, R.. Q&A - Economic analyses for vaccine introduction decisions in low- and middle- income countries. BMC Medicine. 2013;11(1). https://doi.org/10.1186/1741-7015-11-71</li>
<li>Mellor, J. W.. Food Price Policy and Income Distribution in Low-Income Countries. Economic Development and Cultural Change. 1978;27(1), 1-26. https://doi.org/10.1086/451071</li>
<li>Acharya, K. P., Ghimire, T. R., Subramanya, S. H.. Access to and equitable distribution of COVID-19 vaccine in low-income countries. npj Vaccines. 2021;6(1). https://doi.org/10.1038/s41541-021-00323-6</li>
<li>Camfield, L., Esposito, L.. A Cross-Country Analysis of Perceived Economic Status and Life Satisfaction in High- and Low-Income Countries. World Development. 2014;59, 212-223. https://doi.org/10.1016/j.worlddev.2014.01.018</li>
<li>Unknown. Health Expenditure and Economic Development in Low-and Middle-Income Countries. Jurnal Ekonomi Malaysia. 2018;52(3). https://doi.org/10.17576/jem-2018-5203-14</li>
<li>Whetham, E. H., Brenner, Y. S.. Agriculture and the Economic Development of Low Income Countries.. The Economic Journal. 1972;82(326), 793. https://doi.org/10.2307/2230055</li>
<li>Msusa, K. P., Rogalski-Salter, T., Mandi, H., Clemens, R.. Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries. Vaccine. 2022;40(9), 1261-1270. https://doi.org/10.1016/j.vaccine.2022.01.037</li>
<li>de Francisco (Shapovalova), N., Donadel, M., Jit, M., Hutubessy, R.. A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine. 2015;33(48), 6537-6544. https://doi.org/10.1016/j.vaccine.2015.10.066</li>
<li>Akinyemiju, T. F.. Socio-Economic and Health Access Determinants of Breast and Cervical Cancer Screening in Low-Income Countries: Analysis of the World Health Survey. PLoS ONE. 2012;7(11), e48834. https://doi.org/10.1371/journal.pone.0048834</li>
<li>Rosenzweig, M. R.. Payoffs from Panels in Low-Income Countries: Economic Development and Economic Mobility. American Economic Review. 2003;93(2), 112-117. https://doi.org/10.1257/000282803321946903</li>
<li>Hayman, B., Kumar Suri, R., Downham, M.. Sustainable vaccine manufacturing in low- and middle-Income countries. Vaccine. 2022;40(50), 7288-7304. https://doi.org/10.1016/j.vaccine.2022.10.044</li>
<li>Levy, V.. Anticipated Development Assistance, Temporary Relief Aid, and Consumption Behaviour of Low-Income Countries. The Economic Journal. 1987;97(386), 446. https://doi.org/10.2307/2232889</li>
<li>Bennett, A., Bar-Zeev, N., Cunliffe, N. A.. Measuring indirect effects of rotavirus vaccine in low income countries. Vaccine. 2016;34(37), 4351-4353. https://doi.org/10.1016/j.vaccine.2016.07.001</li>
<li>Helleiner, G.. Trade, Trade Policy and Economic Development in very Low-Income Countries. The Bangladesh Development Studies. 1992;20(2&3), 55-68. https://doi.org/10.57138/rpqo6427</li>
<li>Sukharev, A.. Comparative analysis the mentality development of the countries with high and low socio-economic characteristics. Ученые записки Института психологии РАН. 2022;2(3), 65-77. https://doi.org/10.38098/proceedigs_2022_02_03_06</li>
<li>Bal Gündüz, Y.. The Economic Impact of Short-term IMF Engagement in Low-Income Countries. World Development. 2016;87, 30-49. https://doi.org/10.1016/j.worlddev.2016.04.012</li>
<li>Krishnamurty, K.. Economic Development and Population Growth in Low Income Countries: An Empirical Study for India. Economic Development and Cultural Change. 1966;15(1), 70-75. https://doi.org/10.1086/450198</li>
<li>Khan, M. S.. Estimating a panel MSK dataset for comparative analyses of national absorptive capacity systems, economic growth, and development in low and middle income countries. PLOS ONE. 2022;17(10), e0274402. https://doi.org/10.1371/journal.pone.0274402</li>
<li>Skivington, K., Matthews, L., Simpson, S., Craig, P., Baird, J., Blazeby, J.. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021;374, n2061-n2061. https://doi.org/10.1136/bmj.n2061</li>
<li>Diamond, P., Hausman, J. A.. Contingent Valuation: Is Some Number Better than No Number?. The Journal of Economic Perspectives. 1994;8(4), 45-64. https://doi.org/10.1257/jep.8.4.45</li>
<li>Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Bräuer, M.. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;386(10010), 2287-2323. https://doi.org/10.1016/s0140-6736(15)00128-2</li>
<li>Jamison, D. T., Summers, L. H., Alleyne, G. A., Arrow, K. J., Berkley, S., Binagwaho, A.. Global health 2035: a world converging within a generation. The Lancet. 2013;382(9908), 1898-1955. https://doi.org/10.1016/s0140-6736(13)62105-4</li>
<li>Vollset, S. E., Goren, E., Yuan, C., Cao, J., Smith, A., Hsiao, T.. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. The Lancet. 2020;396(10258), 1285-1306. https://doi.org/10.1016/s0140-6736(20)30677-2</li>
<li>Starrs, A. M., Ezeh, A. C., Barker, G., Basu, A., Bertrand, J. T., Blum, R.. Accelerate progress—sexual and reproductive health and rights for all: report of the Guttmacher– Lancet Commission. The Lancet. 2018;391(10140), 2642-2692. https://doi.org/10.1016/s0140-6736(18)30293-9</li>
<li>Sachs, J. D., McArthur, J. W., Schmidt‐Traub, G., Kruk, M. E., Bahadur, C., Faye, M.. Ending Africa's Poverty Trap. Brookings Papers on Economic Activity. 2004;2004(1), 117-240. https://doi.org/10.1353/eca.2004.0018</li>
<li>Borghans, L., Duckworth, A., Heckman, J. J., Weel, B. t.. The Economics and Psychology of Personality Traits. The Journal of Human Resources. 2008;43(4), 972-1059. https://doi.org/10.1353/jhr.2008.0017</li>
<li>O’Donnell, O.. Access to health care in developing countries: breaking down demand side barriers. Cadernos de Saúde Pública. 2007;23(12), 2820-2834. https://doi.org/10.1590/s0102-311x2007001200003</li>
</ol>
</article>